Samson Christopher, du Rand Alex, Hunt John, Whitford Whitney, Jacobsen Jessie, Sheppard Hilary
School of Biological Sciences, University of Auckland, Auckland, New Zealand.
J R Soc N Z. 2024 May 9;55(6):2440-2463. doi: 10.1080/03036758.2024.2347968. eCollection 2025.
Gene editing therapies are designed to minimise off-target editing. However, it is not widespread practice for common polymorphisms to be considered when identifying potential off-target sites . Nevertheless, genetic variants should be included as they have the potential to alter existing, or to generate new, off-target sites. To facilitate the consideration of common polymorphisms when designing targeted gene therapies we developed PopOff, a web-based tool that integrates minor allele frequencies from the gnomAD variant database into an off-target analysis. We used PopOff to analyse predicted off-target loci from guide RNAs used in four clinical trials and thirty-four research publications. From an analysis of sixty guides, we identified that approximately 20% of off-target loci overlap with a common polymorphism. Of these sites, 6.93% contained variants that reduce the level of mismatch between the off-target locus and guide, and therefore may increase off-target cleavage. In addition, we identified that 0.34% of common polymorphisms generated novel PAM sites, resulting in off-target loci that standard workflows would miss. Our findings demonstrate that common polymorphisms should be considered when designing guides to maximise the safety of CRISPR-based gene therapies. However, this may be problematic in populations where the breadth of genetic diversity remains uncharacterised.
基因编辑疗法旨在尽量减少脱靶编辑。然而,在识别潜在脱靶位点时,通常不会普遍考虑常见的多态性。尽管如此,基因变异仍应被纳入考虑,因为它们有可能改变现有的脱靶位点或产生新的脱靶位点。为了在设计靶向基因疗法时便于考虑常见的多态性,我们开发了PopOff,这是一种基于网络的工具,它将gnomAD变异数据库中的次要等位基因频率整合到脱靶分析中。我们使用PopOff分析了四项临床试验和34篇研究出版物中使用的引导RNA预测的脱靶位点。通过对60个引导序列的分析,我们发现约20%的脱靶位点与常见的多态性重叠。在这些位点中,6.93%包含可降低脱靶位点与引导序列之间错配水平的变异,因此可能会增加脱靶切割。此外,我们发现0.34%的常见多态性产生了新的PAM位点,导致标准工作流程会遗漏的脱靶位点。我们的研究结果表明,在设计引导序列时应考虑常见的多态性,以最大限度地提高基于CRISPR的基因疗法的安全性。然而,在遗传多样性广度仍未明确的人群中,这可能会有问题。